<DOC>
	<DOCNO>NCT01253707</DOCNO>
	<brief_summary>First human , open-label , sequential dose escalation expansion study AMG 337 subject advance solid tumor .</brief_summary>
	<brief_title>A Study AMG 337 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Men woman ≥ 18 year old Subjects must pathologically document , definitively diagnose , advance solid tumor Subjects primary central nervous system ( CNS ) tumor metastases resect received radiation therapy end least 4 week prior study day 1 eligible provide meet follow criterion : ) residual neurological symptom grade ≤ 1 ; 2 ) dexamethasone treatment ; c ) followup MRI show new lesion appear Measurable disease per RECIST guideline ( subject nonmeasurable , evaluable disease also eligible dose escalation portion study ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Competent sign date Institutional Review Board approve inform consent form Adequate hematologic renal function determine laboratory blood urine test Men woman reproductive potential , unwilling practice highly effective method birth control duration study continue 2 week ( woman ) 12 week ( men ) receive last dose study drug . Women lactating/breastfeeding plan become pregnant duration study History bleed diathesis Myocardial infarction within 6 month study day 1 , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication , uncontrolled hypertension A baseline ECG QTc &gt; 470 m Active infection requiring ( IV ) antibiotic within 2 week study enrollment Significant gastrointestinal disorder ( ) , opinion investigator , may influence drug absorption Known positive test HIV Known acute chronic hepatitis B hepatitis C infection determine serologic test Antitumor therapy within 28 day study day 1 include chemotherapy , antibody therapy , retinoid therapy , investigational agent Major surgery within 30 day study day 1 Any comorbid medical disorder may increase risk toxicity , opinion investigator sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>C-met inhibitor</keyword>
</DOC>